TYK37: Difference between revisions
No edit summary |
m Text replacement - "<p style="text-align: center;"> About Test Your Knowledge</p>" to "<p style="text-align: center;"> About Test Your Knowledge</p> Category:TYK" |
||
| Line 24: | Line 24: | ||
<p style="text-align: center;">[[TYK36|<Prev Question]] --- [[TYK38|Next Question>]]</p> | <p style="text-align: center;">[[TYK36|<Prev Question]] --- [[TYK38|Next Question>]]</p> | ||
<p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | <p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | ||
[[Category:TYK]] | |||
Latest revision as of 02:38, 25 September 2026
Which of the following neuromuscular blocking agents (NMBA) has a clinically significant metabolite in patients with renal failure?
A. Vecuronium
B. Rocuronium
C. Cisatracurium
D. Mivacurium
Answer
The answer is A. Vecuronium undergoes 30-40 metabolism in the LIVER. Its elimination is mixed (40-50% by the kidney and 50-60% by the liver). However, the extensive metabolism in the liver produces a 3-OH metabolite. This metabolite will accumulate in renal failure and is active with an 80% potency of vecuronium. Rocuronium has no metabolism or active metabolites. Its is eliminated by the kidney (10-25%) and the liver (70%). Cisatracurium undergoes Hoffman elimination (77%) with some kidney elimination (16%). Mivacurium is metabolized by butyrylcholinesterase (95-98%) with minor renal elimination (<5%). Mivacurium and cistracurium have some metabolites, but these are not known to have any significant clinical effect.
Notes